Pharmacotherapeutic management of pulmonary sarcoidosis

American Journal of Respiratory Medicine

Volumn 2, Issue 4, 2003, Pages 311-320

  Fazzi, Piera ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BUDESONIDE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE ANTIBODY; CYTOTOXIC AGENT; DEFLAZACORT; DIPEPTIDYL CARBOXYPEPTIDASE; FLUTICASONE PROPIONATE; GALLIUM 67; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 15; MELATONIN; METHOTREXATE; MONOCLONAL ANTIBODY; OXYPHENBUTAZONE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; PREDNISONE; THALIDOMIDE; UNINDEXED DRUG;

BONE DISEASE; CARCINOGENESIS; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; EYE TOXICITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPERTRICHOSIS; INFECTION; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; NAUSEA; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; RETINA INJURY; REVIEW; SARCOIDOSIS; SKIN MANIFESTATION; SYMPTOMATOLOGY;

EID: 0041384486     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256659     Document Type: Review

References (52)

1. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/ European Respiratory Society/ World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-73
2. Semenzato G, Agostini C, Zambello R, et al. Activated T cells with immunoregulatory functions at different sites of involvement in sarcoidosis: phenotypic and functional evaluations. Ann N Y Acad Sci 1986; 465: 56-73
3. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51: 238-47
4. Costabel U. Sensitivity and specificity of BAL findings in sarcoidosis. Sarcoidosis 1992; 9 Suppl. 1: 211-4
5. Sulavik SB, Spencer RP, Weed DA, et al. Recognition of distinctive patterns of gallium-67 distribution in sarcoidosis. J Nucl Med 1990; 31: 1909-14
6. Allen RK. A review of angiotensin converting enzyme in health and disease. Sarcoidosis 1991; 8: 95-100
7. Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis 1993; 147: 1598-600
8. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149: 893-8
9. Siltzbach LE. Effects of cortisone in sarcoidosis: a study of thirteen patients. Am J Med 1952; 12: 139-60
10. James DG, Carstairs LS, Trowell J, et al. Treatment of sarcoidosis: report of a controlled therapeutic trial. Lancet 1967; II: 526-8
11. Sharma OP, Colp C, Williams Jr MH. Course of pulmonary sarcoidosis with and without corticosteroid therapy as determined by pulmonary function studies. Am J Med 1966; 41: 541-51
12. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest 1997; 111: 623-31
13. Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973; 107: 609-14
14. Rizzato G, Fraioli P, Montemurro L. Long-term therapy with deflazacort in chronic sarcoidosis. Chest 1991; 99: 301-8
15. Fazzi P, Solfanelli S, Begliomini E, et al. 67Ga scan, symptoms and treatment in sarcoidosis. Sarcoidosis 1993; 10 (2): 155-6
16. Selroos OB. Use of budesonide in the treatment of pulmonary sarcoidosis. Ann N Y Acad Sci 1986; 465: 713-21
17. Alberts C, van der Mark TW, Jansen HM, et al. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Eur Respir J 1995; 8: 682-8
18. du Bois RM, Greenhalgh PM, Southcott AM, et al. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999; 13: 1345-50
19. Di Mauro, Fazzi P, Solfanelli S, et al. Efficacy of inhaled budesonide on pulmonary activity in sarcoidosis. Proceedings of the Joint Meeting World Association of Sarcoidosis and Other Granulomatous Disorders and British Society for Allergy and Clinical Immunology; 1995 Oct 15-20; London, P/092, 47
20. Fazzi P, Sbragia P, Solfanelli S, et al. Functional significance of the decreased attenuation sign on expiratory CT in pulmonary sarcoidosis: report of four cases. Chest 2001; 119: 1270-4
21. Pietinalho A, Tukiainen P, Haahtela T, et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002; 121: 24-31
22. Kataria YP. Chlorambucil in sarcoidosis. Chest 1980; 78: 36-43
23. Sahgal S, Sharma O. Fatal herpes simplex infection during chlorambucil therapy for sarcoidosis. J R Soc Med 1984; 77: 144-6
24. Demeter SL. Myocardial sarcoidosis unresponsive to steroids: treatment with cyclophosphamide. Chest 1988; 94: 202-3
25. Lower EE, Broderick JP, Brott TG, et al. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157 (16): 1864-8
26. Bullmann C, Faust M, Hoffmann A, et al. Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis. Eur J Endocrinol 2000; 142 (4): 365-72
27. Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990; 299: 153-7
28. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155: 846-51
29. Tolman KG, Clegg DO, Lee RG, et al. Methotrexate and the liver. J Rheumatol 1985; 12 Suppl. 12: 29-34
30. White DA, Rankin JA, Stover DE, et al. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis 1989; 139 (1): 18-21
31. Rebuck AS, Stiller CR, Braude AC, et al. Cyclosporine for pulmonary sarcoidosis [abstract]. Lancet 1984; I: 1174
32. Hammond JMJ, Bateman ED. Successful treatment of life-threatening steroid-resistant pulmonary sarcoidosis with cyclosporine in a patient with systemic lupus erythematosus. Respir Med 1990; 84: 77-80
33. Martinet Y, Pinkston P, Saltini C, et al. Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Respir Dis 1988; 138: 1242-8
34. Wyser CP, van Schalkwyk EM, Alheit B, et al. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med 1997; 156: 1371-6
35. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144 (2): 291-6
36. Lewis CJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 87-92
37. Muller-Quernheint J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-22
38. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000; 60 (2): 274-88
39. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866-9
40. Rousseau L, Beylot-Barry M, Doutre M-S, et al. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol 1998; 134: 1045-6
41. Fazzi P, Manni E, Barachini P, et al. Thalidomide in pulmonary and cutaneous sarcoidosis [abstract]. 3rd Mediterranean Congress on Thoracic Diseases; 2000 Nov 1-4; Crete, OPG3, 82
42. Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155 (5): 1665-9
43. Siltzbach LE, Tierstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl 1964; 425: 302-8
44. Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25 dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med 1989; 111: 437-8
45. Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol 1998; 55: 1248-54
46. Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160 (1): 192-7
47. Cagnoni ML, Lombardi A, Cerinic MC, et al. Melatonin for treatment of chronic refractory sarcoidosis. [letter]. Lancet 1995; 346: 1229-30
48. Cagnoni ML, Pignone A, Lombardi A, et al. Melatonin in the treatment of cutaneous sarcoidosis [abstract]. J Eur Acad Dermatol Venereol 1995; 5 (1001): 163
49. Cagnoni ML, Pignone A, Cerinic MM, et al. Melatonin: a new therapeutical approach in the treatment of lupus pernio [abstract]. J Eur Acad Dermatol Venereol 1997; 9 (1001): 154
50. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-4
51. DeRemee RA. The present status of treatment of pulmonary sarcoidosis: a house divided. Chest 1977; 71: 388-93
52. Baughman RP, Lower EE. New treatment for sarcoidosis: where's the proof? Eur Respir J 1999; 14: 1000-1